港股異動 | 創新奇智(2121.HK)逆勢漲近10% 創2個月新高
格隆匯4月19日丨“AI+製造”第一股創新奇智(2121.HK)漲幅擴大至9.7%,報19.96港元創2個月新高價,總市值94.8億港元。此前公佈的年度業績顯示,2021年營業收入達人民幣8.61億元,同比增長86.3%。格隆匯文章《創新奇智(2121.HK):營收同增86.3%領跑AI行業,但首份財報的意義不止於此》提到,營收不僅超出市場預期,更是遠勝所有已公佈業績的同業競爭對手。在如此高增長營收的帶動下,公司的毛利潤達2.67億元,同比增長98.5%。預計隨着公司業務的放量,成長邏輯還將持續增強,因此未來公司的成長具備較高確定性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.